Biognosys Communication in Response to COVID-19 - Biognosys

Biognosys Communication in Response to COVID-19

Hello,

We hope that you and your loved ones are safe during this challenging time.

As COVID-19 continues to impact the globe, we want to inform you of how Biognosys is prepared to ensure that we continue to work with our clients during this period.

At this time our offices and facility in Schlieren, Switzerland, remain open and operational. We have implemented a work from home policy for non-operational personnel to support the measures that the Swiss Federal government enacted to slow the spread of the virus. There is currently no interruption to our contract research services and the shipping of software and reagent products. Our business continuity plan and investment in communication technology ensure that during this period we can offer our clients uninterrupted access.

We will continue to update all our stakeholders as developments occur, and in the meantime, we hope everyone remains safe and healthy. Please do not hesitate to reach out to us with any questions you have.

Thank you, with kind regards,

Oliver Rinner
CEO, Biognosys AG

 

View as PDF

Back to News overview

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    New: Drug Target Validation

    Reveal Binding Sites with Structural Proteomics

    New: Drug Target Validation

    Reveal Compound Binding Sites with Structural Proteomics

    Learn More